Main Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $132K | Hold |
1,030
| – | – | 0.01% | 64 |
|
|
2025
Q4 | $126K | Hold |
1,030
| – | – | 0.01% | 62 |
|
|
2025
Q3 | $103K | Hold |
1,030
| – | – | 0.01% | 71 |
|
|
2025
Q2 | $85K | Hold |
1,030
| – | – | 0.01% | 73 |
|
|
2025
Q1 | $84K | Sell |
1,030
-45,200
| -98% | -$4.04M | 0.01% | 75 |
|
|
2024
Q4 | $4.16M | Sell |
46,230
-20,330
| -31% | -$1.97M | 0.34% | 30 |
|
|
2024
Q3 | $6.58M | Sell |
66,560
-189,620
| -74% | -$18.6M | 0.54% | 29 |
|
|
2024
Q2 | $23.8M | Buy |
256,180
+32,100
| +14% | +$2.88M | 1.96% | 14 |
|
|
2024
Q1 | $21.3M | Buy |
224,080
+1,500
| +0.7% | +$139K | 1.82% | 19 |
|
|
2023
Q4 | $19.9M | Buy |
222,580
+2,575
| +1% | +$191K | 1.95% | 18 |
|
|
2023
Q3 | $16.1M | Buy |
220,005
+6,686
| +3% | +$534K | 1.63% | 20 |
|
|
2023
Q2 | $17.7M | Sell |
213,319
-261,501
| -55% | -$21.9M | 1.8% | 18 |
|
|
2023
Q1 | $36.2M | Buy |
474,820
+952
| +0.2% | +$79K | 3.84% | 9 |
|
|
2022
Q4 | $39.3M | Buy |
473,868
+105,733
| +29% | +$8.56M | 4.54% | 7 |
|
|
2022
Q3 | $29.2M | Buy |
368,135
+5,884
| +2% | +$496K | 3.61% | 8 |
|
|
2022
Q2 | $26.9M | Buy |
362,251
+86,869
| +32% | +$6.52M | 3.21% | 8 |
|
|
2022
Q1 | $24.8M | Buy |
275,382
+213,301
| +344% | +$19.7M | 2.55% | 12 |
|
|
2021
Q4 | $6.95M | Sell |
62,081
-2,216
| -3% | -$267K | 0.7% | 33 |
|
|
2021
Q3 | $8.08M | Buy |
64,297
+1,289
| +2% | +$166K | 0.87% | 30 |
|
|
2021
Q2 | $8.53M | Sell |
63,008
-745
| -1% | -$97.9K | 0.92% | 27 |
|
|
2021
Q1 | $8.65M | Sell |
63,753
-45,095
| -41% | -$6.75M | 0.96% | 31 |
|
|
2020
Q4 | $15.3M | Sell |
108,848
-5,620
| -5% | -$720K | 1.96% | 19 |
|
|
2020
Q3 | $12.8M | Buy |
114,468
+9,655
| +9% | +$1.08M | 1.79% | 18 |
|
|
2020
Q2 | $11.7M | Buy |
104,813
+5,742
| +6% | +$566K | 1.86% | 19 |
|
|
2020
Q1 | $7.67M | Sell |
99,071
-8,680
| -8% | -$769K | 1.42% | 23 |
|
|
2019
Q4 | $10.2M | Buy |
107,751
+4,223
| +4% | +$365K | 1.38% | 21 |
|
|
2019
Q3 | $7.89M | Sell |
103,528
-54,390
| -34% | -$4.52M | 1.1% | 22 |
|
|
2019
Q2 | $13.9M | Buy |
157,918
+845
| +0.5% | +$72.1K | 2.01% | 16 |
|
|
2019
Q1 | $14.2M | Buy |
157,073
+2,029
| +1% | +$173K | 2.09% | 17 |
|
|
2018
Q4 | $11.1M | Buy |
155,044
+2,261
| +1% | +$182K | 1.7% | 18 |
|
|
2018
Q3 | $14.6M | Sell |
152,783
-9,069
| -6% | -$879K | 2.11% | 18 |
|
|
2018
Q2 | $15.4M | Buy |
161,852
+1,476
| +0.9% | +$136K | 2.07% | 17 |
|
|
2018
Q1 | $14.1M | Buy |
160,376
+9,658
| +6% | +$882K | 1.93% | 17 |
|
|
2017
Q4 | $12.8M | Buy |
150,718
+4,618
| +3% | +$387K | 1.86% | 18 |
|
|
2017
Q3 | $12.6M | Sell |
146,100
-260
| -0.2% | -$20.8K | 1.88% | 17 |
|
|
2017
Q2 | $11.3M | Buy |
146,360
+978
| +0.7% | +$69.4K | 1.73% | 17 |
|
|
2017
Q1 | $10.1M | Buy |
+145,382
| New | +$9.76M | 1.62% | 16 |
|
Other funds holding XBI
Main Management's XBI Position: Q1 2026 in Review
Main Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 1,030 shares worth $132K. The position accounts for 0.01% of the portfolio, ranked #64.
Main Management first reported a position in XBI in Q1 2017 and has held it in 37 quarters since. The position peaked at $39.3M in Q4 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Main Management held 1,030 shares of State Street SPDR S&P Biotech ETF worth $132K as of Q1 2026.
- Main Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
- State Street SPDR S&P Biotech ETF made up 0.01% of Main Management's portfolio in Q1 2026, its #64 holding.
- Main Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 37 quarters since.
- Main Management's State Street SPDR S&P Biotech ETF position peaked at $39.3M in Q4 2022.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Main Management's 13F filing for Q1 2026, filed 15 May 2026.